This report examines the multiple sclerosis population in Medicare Part D. Study results include characteristics of enrollees using disease-modifying therapies (DMTs) and show how cost sharing and therapies differed by demographic and coverage characteristics. Due to the cost of DMT, beneficiaries not receiving the low-income subsidy or employer-sponsored coverage may have to pay large out-of-pocket amounts. This study also examines the use of MS-related, non-DMT drugs to treat MS-related conditions.

This report was commissioned by Biogen.